Roche tops pharma rivals for reputation among rare disease patient groups

Roche was ranked first for corporate reputation in the field of rare disease by patient groups surveyed for PatientView’s annual report.

The Swiss pharma giant topped rivals BioMarin and Amgen, who finished second and third, respectively.